The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Jonathan A. Ledermann

University College London (UCL) Cancer Institute

UCL & UCL Hospitals Comprehensive Biomedical Research Centre

90 Tottenham Court Rd.

London W1T 4TJ

United Kingdom

[email]@ctc.ucl.ac.uk

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • University College London (UCL) Cancer Institute, UCL & UCL Hospitals Comprehensive Biomedical Research Centre, 90 Tottenham Court Rd., London W1T 4TJ, United Kingdom. 2012
  • Cancer Research UK and University College London Cancer Trials Centre, UCL Cancer Institute, University College London, 90 Tottenham Court Rd. 2011
  • UCL Hospitals, UCL Cancer Institute, London, United Kingdom. 2010
  • UCL Cancer Institute, University College London, London W1T 4TJ, UK. 2010
  • Department of Oncology, University College London, London, United Kingdom. 2004 - 2008

References

  1. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., Matei, D., Macpherson, E., Watkins, C., Carmichael, J., Matulonis, U. N. Engl. J. Med. (2012) [Pubmed]
  2. Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer. Ledermann, J.A., Hackshaw, A., Kaye, S., Jayson, G., Gabra, H., McNeish, I., Earl, H., Perren, T., Gore, M., Persic, M., Adams, M., James, L., Temple, G., Merger, M., Rustin, G. J. Clin. Oncol. (2011) [Pubmed]
  3. Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer. Ledermann, J.A., Gabra, H., Jayson, G.C., Spanswick, V.J., Rustin, G.J., Jitlal, M., James, L.E., Hartley, J.A. Clin. Cancer Res. (2010) [Pubmed]
  4. Targeted trials in ovarian cancer. Ledermann, J.A., Raja, F.A. Gynecol. Oncol. (2010) [Pubmed]
  5. Lessons learned from a decade of clinical trials of high-dose chemotherapy in ovarian cancer. Ledermann, J.A. Int. J. Gynecol. Cancer (2008) [Pubmed]
  6. How should we manage patients with "platinum-sensitive" recurrent ovarian cancer?. Ledermann, J.A., Wheeler, S. Cancer Invest. (2004) [Pubmed]
 
WikiGenes - Universities